ArticleNature medicine2020
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 274 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
274citing papers in PubMed, 2 pooled it
34.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
274 citing papers in PubMed, 2 syntheses or guidelines pooled it, 434 citations in OpenAlex.
- Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models.Acta neuropathologica communications · 2024Pooled it
- Pooled it
- Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Trial
- Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.Brain : a journal of neurology · 2023Trial
- Repositioning of polyubiquitin alters the pathologic tau filament structure.Nature structural & molecular biology · 2026Article
- Distribution of Big Tau Isoforms in the Human Central and Peripheral Nervous System.Annals of neurology · 2026Article
- Atypical Alzheimer disease: a multi-axis framework toward defining heterogeneity.Nature reviews. Neurology · 2026Review
- Review
- A third-generation, high-affinity biparatopic anti-tau antibody inhibits intracellular tau aggregation seeded by Alzheimer's brain extracts.Alzheimer's research & therapy · 2026Article
- α-Synuclein strain homogeneity in multiple system atrophy subtypes.Brain pathology (Zurich, Switzerland) · 2026Article
- Tau dysfunction in alzheimer's disease: molecular and cellular mechanisms, genetic modulation, and therapeutic perspectives.Molecular biology reports · 2026Review
- Tau seeds induce neurofibrillary tangle formation across brain regions via individual-specific connectivity.Neuron · 2026Article
- tRNA-derived fragments elevated in Alzheimer's disease promote Tau aggregation.bioRxiv : the preprint server for biology · 2026Article
- Tau pathology in epilepsy: emerging mechanisms and translational opportunities.Brain : a journal of neurology · 2026Review
- Article
- Elimination of tau tangles and soluble aggregates with the small molecule ACI-16664 prevents neurodegeneration in vivo.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Functional Implications of Marine Biosurfactants and Their Therapeutic Potential Against Alzheimer's Disease.Food science & nutrition · 2026Review
- Molecular profiling of alpha-synuclein pathology and seeding activity in Parkinson's disease.Acta neuropathologica · 2026Article
- Evidence for different seeding activities of misfolded tau in classical and rapidly progressive Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026Article
- The Effect of Metabolic Syndrome on Alzheimer's Disease: Physical Activity as a Preventive and Therapeutic Measure.Brain sciences · 2026Review
214 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
27 authors at 4 institutions in 1 country.
Simon DujardinAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.ORCID http://orcid.org/0000-0002-5614-341X
Caitlin ComminsAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Aurelien LathuiliereAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Pieter BeerepootHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3721-3213
Analiese R FernandesAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Tarun V KamathAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Mark B De Los SantosAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.ORCID http://orcid.org/0000-0002-7195-5141
Naomi KlicksteinAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Diana L CorjucAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Bianca T CorjucAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Patrick M DooleyAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Arthur ViodeHarvard Medical School, Boston, MA, USA.
Derek H OakleyAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Benjamin D MooreAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Kristina MullinGenetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Dinorah Jean-GillesDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Ryan ClarkDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Kevin AtchisonDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Renee MooreDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Lori B ChibnikAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Rudolph E TanziHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7032-1454
Matthew P FroschHarvard Medical School, Boston, MA, USA.
Alberto Serrano-PozoAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.ORCID http://orcid.org/0000-0003-0899-7530
Fiona ElwoodDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Judith A SteenHarvard Medical School, Boston, MA, USA.
Matthew E KennedyDepartment of Neuroscience, Merck & Co., Boston, MA, USA.
Bradley T HymanAlzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA. bhyman@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-7959-9401
Harvard University · USMassachusetts General Hospital · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USBoston Children's Hospital · US
Funding
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1MResearch Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Sudeshna Das · 2019 to 2026
$36.5MAre multiple tau species toxic in Alzheimer's Disease?RF1AG059789 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 2018 to 2018
$2.7MSynergy between amyloid and tau in Alzheimer's DiseaseRF1AG058674 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 2018 to 2018
$2.6MAstrocyte Reaction in Alzheimer's DiseaseK08AG064039 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI SERRANO-POZO, ALBERTO · 2019 to 2023
$837kComplexity and Heterogeneity of Alzheimer diseaseR56AG061196 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 2019 to 2019
$654kAlzheimer's Association 2018-AARF-591935NIA NIH HHS K08 AG064039NIA NIH HHS P30 AG062421NIA NIH HHS P50 AG005134NIA NIH HHS R56 AG061196NIA NIH HHS RF1 AG058674NIA NIH HHS RF1 AG059789Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) P2ELP3_184403U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1K08AG064039U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1P30AG062421U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1RF1AG058674U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1RF1AG059789
Abstract
Alzheimer's disease (AD) causes unrelenting, progressive cognitive impairments, but its course is heterogeneous, with a broad range of rates of cognitive decline
Indexed as
AgedAged, 80 and overAge of OnsetAlzheimer DiseaseCerebral CortexCognitive DysfunctionFemaleGenetic HeterogeneityHumansMaleMiddle AgedNeurofibrillary TanglesPhosphorylationProtein Aggregation, PathologicalSeverity of Illness Indextau Proteinstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.